Lipocine INC Form 4 insider transactions

Michael Grissinger, a Director of Lipocine Inc., received 2,000 shares of common stock on August 3, 2026.

Lipocine Inc. CEO Mahesh V. Patel acquired stock options for 52,781 shares at an exercise price of $2.49, with vesting scheduled over three years.

Lipocine Inc. director John W. Higuchi acquired stock options with a potential exercise price of $2.19.

Lipocine Inc. director Jill M. Jene acquired stock options for 1,764 shares of common stock.

Lipocine Inc. director Richard Dana Ono acquired 1,764 shares of common stock through the exercise of a right to buy, with a conversion price of $2.19.

Lipocine Inc. director John W. Higuchi acquired 40,000 shares of common stock.

Lipocine Inc. director John W. Higuchi reported the acquisition of 123,000 common shares.

Lipocine Inc. reports a significant stock purchase by its CEO and Director, Mahesh V. Patel.

Lipocine Inc. CEO Mahesh V. Patel acquired 25,000 shares of common stock.

Lipocine Inc.'s CEO, Mahesh V. Patel, was granted 25,000 stock options with an exercise price of $8 per share, vesting over three years.

Lipocine Inc. CEO Mahesh V. Patel was granted 8,629 stock options at an exercise price of $4.20, vesting over three years.

Lipocine Inc.'s Principal Accounting Officer, Krista Fogarty, was granted 20,786 stock options with a $4.2 exercise price, vesting over three years.

Lipocine Inc. Director Richard Dana Ono was granted 1,764 derivative securities, specifically rights to buy common stock, at an exercise price of $3.2 per share, vesting one year from the grant date.

Lipocine Inc. Director Jill M. Jene has acquired 1,764 stock options at an exercise price of $3.20, aligning her interests further with shareholders.

Lipocine Inc. Director and 10% Owner, Spyros Papapetropoulos, was granted 1,764 stock options with an exercise price of $3.20 per share.

Jeffrey Arvin Fink, a Director and 10% Owner of Lipocine Inc. (LPCN), has acquired 1,764 derivative securities (rights to buy common stock) at an exercise price of $3.2 per share, as reported in a recent SEC Form 4 filing.

Lipocine Inc. Director John W. Higuchi has acquired 1,764 derivative securities, specifically rights to buy common stock, at an exercise price of $3.2 per share, as reported in a recent SEC Form 4 filing.

Lipocine's CEO, Mahesh V. Patel, acquired stock options for 10,320 shares, as reported in a Form 4/A filing.

Lipocine's CEO, Mahesh V. Patel, was granted stock options for 16,371 shares at an exercise price of $4.86.

Lipocine's CEO, Mahesh V. Patel, acquired 26,691 stock options on December 23, 2024, at an exercise price of $4.80.

Krista Fogarty, Principal Accounting Officer of Lipocine Inc., acquired stock options for 5,943 shares on December 23, 2024.

Spyros Papapetropoulos, a director of Lipocine Inc., reports the acquisition of stock options.

Director Richard Dana Ono reported the acquisition of stock options and disposal of common stock in Lipocine Inc.

Director Jill M. Jene acquired stock options in Lipocine Inc. on June 5, 2024.

Director John W. Higuchi reports acquisition of Lipocine Inc. shares through option exercise on June 5, 2024.

Director Jeffrey Fink reported the acquisition of stock options in Lipocine Inc. on June 5, 2024.

Lipocine's CEO, Mahesh V. Patel, reports the acquisition of 4,893 shares of common stock and disposal of 112,311 shares.

Krista Fogarty, Principal Accounting Officer of Lipocine Inc., reports the acquisition of restricted stock units.